How much funding has RegCell raised?

RegCell has raised $45.8M in total funding, most recently a Grant round.

Where is RegCell headquartered?

RegCell is headquartered in Emeryville, California, United States.

What industry is RegCell in?

RegCell operates in Biotech, Healthcare.

RegCell

Q: Who are RegCell's investors?

RegCell's investors include Japanese Agency for Medical Research and Development (AMED), Fast Track Initiative,, UTEC - The University.

Restoring self tolerance to the immune system

Emeryville, United States · $45.8M raised

Biotech

Healthcare

Headquarters: Emeryville, California
Employees: 11–50
Business Model: B2B
Website: regcellbio.com

Total Funding: $45.8M
Last Round: $37.3M GrantMar 2025
Rounds: 2

About

RegCell is a clinical-stage cell therapy company headquartered in Emeryville, California, developing regulatory T cell (Treg) therapies to restore immune tolerance in patients with autoimmune diseases such as rheumatoid arthritis, Type 1 diabetes, multiple sclerosis, and lupus. Founded on the Nobel Prize-winning discoveries of Dr. Shimon Sakaguchi — who first characterized Tregs and their role in preventing autoimmunity — RegCell's platform uses epigenetically reprogrammed induced Tregs to deliver antigen-specific immune tolerance rather than broad immunosuppression. The company completed its U.S. headquarters transition in March 2025 following a $45.8M seed financing co-led by Fast Track Initiative and UTEC, and has partnered with Kincell Bio for cell therapy manufacturing toward clinical trials.

Summary

RegCell is a Biotech company based in Emeryville, United States. It has raised $45.8M in total across 2 rounds, most recently a $37.3M Grant round in Mar 2025. Investors include Japanese Agency for Medical Research and Development (AMED), Fast Track Initiative, and UTEC - The University.